Safety, Efficacy of Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups
the Cancer Therapy Advisor take:
Because hepatocellular carcinoma occurs most frequently in patients who are approximately 70 years old, researchers set out to evaluate the safety of sorafenib, the standard of care for patients with advanced hepatocellular carcinoma, in older patients.
The researchers conducted a retrospective analysis from a single institution’s data regarding patients with hepatocellular carcinoma who received sorafenib treatment. The researcher compared the data relating to the safety and effectiveness of sorafenib treatment across age groups. The researchers analyzed the data of 129 patients.
Of these patients, 78 were older than age 70 (60.5%), 51 patients were age 70 or younger (39.5%). The researchers found that the occurrence of dose reduction was comparable between the 2 groups of patients (48.7% vs. 58.8%, respectively). The occurrence of sever toxicities was also comparable (41% vs. 51%, respectively).
The same was true for the rate of hospitalization (9% vs. 13.7%, respectively). Bleeding and asthenia, though, were more common in older adults (the group over age 70). The researchers identified a trend is less treatment interruption in the younger patients compared with the patients over age 70 (25.6% vs. 39.2%, respectively). The younger patients also saw a significant decrease in the rate of treatment discontinuation due to treatment toxicity (24.4% vs. 45.1%, respectively).
Interestingly, the median progression-free survival rate was 5.6 in both groups of patients and the median overall survival was longer in the older age group compared with younger age group (12.6 months vs. 9.6 months, respectively). The researchers concluded that there was not a big distinction between an older or younger patient being treated with sorafenib in terms of treatment safety or efficacy.
However, oncologists should conduct careful baseline evaluation and prepare for toxicity management and discussions regarding antiplatelet therapy discontinuation and caution in PS1 patients, in particular.
Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer